Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercepharma.com
FiercePharma
Get the latest updates from FiercePharma directly as they happen.
Follow now 402 followers
Latest posts
Last updated 7 minutes ago
Valneva to lay off up to 15% of workforce in face of ‘adverse trend’ in travel vaccines
7 minutes ago
Valneva is planning to shrink its headcount by up to 15% as...
BioMarin consolidates staff at Amicus HQ after closing $4.8B deal for rare disease peer
about 16 hours ago
Shortly after locking down its $4.8 billion deal for rare disease compatriot...
FDA Commissioner Marty Makary to resign, capping turbulent tenure: report
about 19 hours ago
Marty Makary, M.D., is resigning as FDA commissioner Tuesday, ending a brief...
Eli Lilly pauses Indian obesity awareness campaign after regulatory notices: report
about 20 hours ago
Eli Lilly has paused an obesity awareness campaign in India in response...
Alkermes’ Lumryz hits phase 3 mark in another sleep disorder, fueling momentum from $2.4B Avadel acquisition
about 22 hours ago
Alkermes has chalked up a quick clinical win from its $2.37 billion...
As public vaccine criticism quiets, RFK Jr. keeps safety inquiries running in background: NYT
about 22 hours ago
Amid apparent overtures from the Trump administration to curb public vaccine criticism...
Pfizer, Arvinas win $85M upfront in Rigel licensing pact for new breast cancer med Veppanu
about 22 hours ago
The deal includes up to $320 million in future milestone payments plus...
Bayer's Eylea declines by 24%, bearing the brunt of biosmilar competition
about 22 hours ago
After staving off significant sales declines for Eylea, Bayer is getting hit...
European Union advances scheme to bolster manufacturing autonomy, avert drug shortages
1 day ago
After positive momentum on the plan in late 2025, European Union lawmakers...
Bicara Therapeutics hires Replimune, Sanofi alum as chief commercial officer
1 day ago
As Bicara Therapeutics lines up for a potential accelerated cancer drug approval...
CSL slashes revenue projection and takes $5B impairment as interim CEO flags R&D misses, market erosion
2 days ago
CSL has slashed its revenue projection for the fiscal year from $15.8...
Partner's bispecific Bizengri nabs FDA national priority nod in rare bile duct cancer
2 days ago
With the program’s seventh approval in the books, the FDA is illustrating...